权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Cancer and Leukemia Group B

癌症和白血病 B 组

基本信息

批准号：
7892673
负责人：
RICHARD L SCHILSKY
金额：
$ 20.14万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-06-01 至 2010-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7892673
关键词：
18 year old Academic Medical Centers Achievement Acute leukemia Address Adjuvant Adjuvant Chemotherapy Adjuvant Therapy Adolescent Adopted Adverse event Advisory Committees Advocate Affect African American Age Allogenic Am 580 American College of Radiology Imaging Network American Society of Clinical Oncology Ancillary Study Antibodies Antineoplastic Agents Applications Grants Archives Area Arsenic Trioxide Arts Attention Autologous Autologous Stem Cell Transplantation Award Azacitidine BCL2 gene Basic Science Behavioral Sciences Biological Biological Assay Biological Markers Biological Markers Biological Products Biologically Based Therapy Biology Bone Density Bone Marrow Transplantation Breast Breast Cancer Prevention Budgets Busulfan CD3 Antigens California Cancer Biology Cancer Control Cancer Patient Cancer Survivor Cancer and Leukemia Group B Candidate Disease Gene Caregivers Caring Categories Cell Transplants Cells Certification Chairperson Characteristics Chemotherapy-Oncologic Procedure Chest Chicago Children&apos s Oncology Group Chimerism Cisplatin Classification Clinical Clinical Pharmacology Clinical Research Clinical Research Associate Clinical Trials Clinical Trials Cooperative Group Clinical Trials Data Monitoring Committees Clinical Trials Design Clinical Trials Network Collaborations Colon Carcinoma Colorectal Cancer Commit Committee Members Communication Communities Community Clinical Oncology Program Community Hospitals Comorbidity Companions Complex Computer software Concept Review Consent Controlled Clinical Trials Core Facility Correlative Study Counseling Credentialing Critiques DNA DNA Microarray Chip Data Data Analyses Data Collection Data Set Databases Dependency Development Diagnosis Diagnostic Discipline Discipline of Nursing Disease Disease remission Disease-Free Survival Disorder by Site Documentation Dose Drug Evaluation Drug Formulations Drug Industry Drug Kinetics Drug resistance Dysmyelopoietic Syndromes ERBB2 gene Early Diagnosis Eastern Cooperative Oncology Group Economics Education Elderly Elements Eligibility Determination Enrollment Ensure Enzymes Epidemiology Equilibrium Esophageal Ethnic group Evaluation Event Evolution Exhibits Face Faculty Feedback Follicular Lymphoma Fostering Freezing Functional disorder Funding Future Generations Genes Genetic Polymorphism Genitourinary system Geriatric Assessment Goals Grant Group Processes Health Health Services Healthcare Hematopoietic Hispanics Histology Hodgkin Disease Homologous Transplantation Hospitals Hour Human Resources Image Imaging technology Immune Immunophenotyping Incidence Individual Inferior Institutes Institution International Intervention Investigational New Drug Application Kidney Knowledge Laboratories Laboratory Study Latino Lead Leadership Learning Length Libraries Link Living Costs Location Lung Lymphedema Lymphography Lymphoma Magnetic Resonance Imaging Maintenance Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of pancreas Malignant neoplasm of prostate Malignant neoplasm of testis Malignant neoplasm of urinary bladder Manuscripts Maximum Tolerated Dose Measurement Medical Medical Oncologist Medicine Mentors Mesothelioma Methodology Micrometastasis Microscopy Minority Mission Modality Modeling Molecular Molecular Analysis Molecular Cytogenetics Molecular Profiling Molecular Target Monitor Monoclonal Antibodies Monoclonal Antibody Therapy Morbidity - disease rate Multiple Myeloma Mutation NCI Board of Scientific Advisors Names Natural History Nelarabine Neoadjuvant Therapy Nephrectomy New Agents Newly Diagnosed Non-Small-Cell Lung Carcinoma North Carolina North Central Cancer Treatment Group Nurses Nursing Societies Observational Study Office for Human Research Protections Ohio Oncologic Nursing Oncology Nurse Online Systems Operative Surgical Procedures Oral Organ Outcome P-Glycoprotein P-Glycoproteins PET/CT scan Paclitaxel Pain Paper Paraffin Embedding Participant Pathologist Pathology Patient Care Patient Outcomes Assessments Patient Recruitments Patients Pattern Peer Review Pelvis Performance Peripheral Nervous System Diseases Personal Satisfaction Pharmaceutical Preparations Pharmacists Pharmacodynamics Pharmacogenetics Pharmacogenomics Pharmacology Phase Phase I Clinical Trials Phase I/II Trial Phase II Clinical Trials Phase III Clinical Trials Physicians Pilot Projects Plasma Play Policies Population Population Sciences Positioning Attribute Positron-Emission Tomography Postdoctoral Fellow Preparation Prevention Preventive Intervention Principal Investigator Procedures Process Productivity Prognostic Marker Prostate Proteins Protocols documentation Publications Publishing Pulmonology Qualifying Quality Control Quality of life Radiation Oncologist Radiation Oncology Radiation therapy Radiology Specialty Randomized Clinical Trials Randomized Controlled Clinical Trials Recommendation Recording of previous events Records Recruitment Activity Recurrent disease Regulatory Affairs Relapse Relative (related person)Renal Cell Carcinoma Renal carcinoma Reporting Request for Applications Research Research Activity Research Design Research Ethics Committees Research Infrastructure Research Personnel Research Project Grants Residual Neoplasm Resistance Resources Revlimid Risk Role Safety Sample Size Sampling San Francisco Schedule Science Scientist Seasons Secure Series Services Signal Pathway Site Site Visit Social Adjustment Solid Solid Neoplasm Southwest Oncology Group Specific qualifier value Staging Stem cells Structure Supportive care Surface Antigens Surgeon Surgical Oncology Surveys Survival Rate Survivors Symptoms System Systemic Therapy T-Lymphocyte Tamoxifen Techniques Technology Telephone Testing Therapeutic Therapeutic Index Therapeutic Studies Therapeutics Committee Therapy Clinical Trials Thoracic Surgical Procedures Time Tissue Banking Tissue Banks Tissue Sample Tissues Toxic effect Training Training Activity Translational Research Translational Research Working Group Transplantation Trastuzumab Travel Treatment Efficacy Treatment Protocols Treatment outcome Triage Tumor Angiogenesis Tumor Biology Tumor Markers Tumor Tissue Uncertainty Underrepresented Minority Underserved Population United States Universities University of Chicago Cancer Research Center Update Upper arm Urine Urogenital Cancer Urology Vascular Endothelial Growth Factors Veterans Vision Woman Work Writing Zoledronic Acid abstracting advanced disease age group anticancer research base bevacizumab biobank bisphosphonate bladder Carcinoma breast lumpectomy breast surgery cancer care cancer imaging cancer prevention cancer surgery cancer therapy cancer type capecitabine career cell killing chemotherapy chronic graft versus host disease clinical practice conditioning cooperative study cost cost effectiveness data collection methodology design disease characteristic drug development evidence base experience falls functional outcomes gastrointestinal gemcitabine genome-wide graft vs host disease health related quality of life high risk hormone therapy human subject protection improved inhibitor/antagonist innovation insight interdisciplinary approach interest irinotecan kidney cell leukemia leukemia/lymphoma malignant breast neoplasm meetings member minimally invasive molecular imaging mortality multidisciplinary named group neoplasm registry neoplasm resource neoplastic cell new technology novel novel strategies novel therapeutics nursing intervention older patient older women oncology organizational structure outcome forecast patient population population based prevent professor progesterone 11-hemisuccinate-(2-iodohistamine)programs protocol development quality assurance radiologist research clinical testing respiratory response skills small molecule standard care standard of care statistical center stem success survivorship symptom management technology/technique time use tool transmission process treatment response treatment strategy treatment trial trial comparing tumor tumor progression urinary gonadotropin fragment virtual working group young adult

项目摘要

DESCRIPTION (Provided by applicant): The CALGB is comprised of 26 academic medical centers and over 200 affiliated community hospitals joined in the pursuit of improved cancer treatment and better understanding of tumor biology and cancer treatment outcomes via the conduct of controlled clinical trials. Over 4,000 members of the Group including oncology physicians, radiologists, pathologists, statisticians, clinical research associates, oncology nurses, pharmacists, health outcomes researchers, and basic scientists participate in these studies. From 25-30 phase III protocols are active at any one time, along with phase II and phase I studies that provide preliminary data required for the appropriate design of large scale randomized trials. Multidisciplinary disease committees of the Group design and implement protocols for the treatment of patients with leukemia, lymphoma, breast, respiratory, Gl and GU cancer. Modality committees, including Leukemia Correlative Sciences, Imaging, Pharmacology and Experimental Therapeutics, Surgery, Transplant, Cancer in the Elderly, Cancer Control and Health Outcomes, and Oncology Nursing provide expertise that enhances the contribution of these disciplines to CALGB studies. Scientific resources committees, including Clinical Research Associates, Pathology and Radiation Oncology, provide essential quality assurance and training activities for the Group. Major areas of emphasis in CALGB include development of innovative treatments for patients with cancer; studies of molecular predictors of prognosis and response to therapy; studies of the pharmacokinetics, pharmacodynamics and pharmacogenetics of new and established anticancer drugs; evaluation of minimally invasive surgical techniques and novel imaging technologies; determining the cost and cost-effectiveness of new cancer therapies; evaluating the impact of cancer and its treatment on the quality of life of cancer patients and their caregivers; developing new strategies for cancer prevention; and addressing the needs of special populations, particularly minorities and the elderly. A new core facility in cancer imaging was established to provide central review and archiving of PET and CT images and to set standards for image acquisition and transmission at CALGB institutions. Three new molecular reference laboratories are proposed in this application to provide biomarker assessments that are necessary to determine patient eligibility or treatment assignment in CALGB studies of targeted therapies. Three established biorepositories collect, archive and distribute frozen and paraffin-embedded solid tumor tissues, leukemia cells, plasma, serum, urine and DNA for correlative science studies.

描述（由申请人提供）：CALGB 由 26 个学术医疗中心和 200 多家附属社区医院组成，致力于通过开展对照临床试验来改善癌症治疗并更好地了解肿瘤生物学和癌症治疗结果。该小组有超过 4,000 名成员，包括肿瘤科医生、放射科医生、病理学家、统计学家、临床研究员、肿瘤护士、药剂师、健康结果研究人员和基础科学家参与这些研究。 25-30 个 III 期方案随时处于活动状态，同时还有 II 期和 I 期研究，为大规模随机试验的适当设计提供所需的初步数据。该集团的多学科疾病委员会设计并实施治疗白血病、淋巴瘤、乳腺癌、呼吸道癌、GI和GU癌症患者的方案。模态委员会，包括白血病相关科学、影像、药理学和实验治疗、外科、移植、老年人癌症、癌症控制和健康结果以及肿瘤护理，提供专业知识，增强这些学科对 CALGB 研究的贡献。科学资源委员会，包括临床研究助理、病理学和放射肿瘤学，为集团提供必要的质量保证和培训活动。 CALGB 的主要重点领域包括为癌症患者开发创新疗法；预后和治疗反应的分子预测因子的研究；新药和现有抗癌药物的药代动力学、药效学和药物遗传学研究；微创手术技术和新型成像技术的评估；确定新癌症疗法的成本和成本效益；评估癌症及其治疗对癌症患者及其护理人员生活质量的影响；制定癌症预防新策略；满足特殊人群的需求，特别是少数民族和老年人的需求。建立了一个新的癌症成像核心设施，以提供 PET 和 CT 图像的集中审查和存档，并为 CALGB 机构的图像采集和传输制定标准。本申请提出了三个新的分子参考实验室，以提供确定患者资格或靶向治疗 CALGB 研究中的治疗分配所必需的生物标志物评估。三个已建立的生物样本库收集、存档和分发冷冻和石蜡包埋的实体瘤组织、白血病细胞、血浆、血清、尿液和 DNA，用于相关科学研究。